In the largest study to date of rapid TB tests used by the NHS, a team led by researchers at Imperial College London found that available tests are not sensitive enough to rule out a diagnosis of TB in suspected cases, and so have limited clinical use.
The research , published in the journal Lancet Infectious Diseases , also looked at a new second generation rapid blood test, developed at Imperial, and found it to be substantially more accurate than the existing tests.
According to the team, once implemented the new test could enable doctors to quickly detect or rule out TB infection and help them to distinguish patients who need further investigation and treatment from those who do not and pose no infectious risk to others.
Professor Ajit Lalvani , Chair in Infectious Diseases at the National Heart & Lung Institute at Imperial College London, who led the study, said: “Tens of thousands of patients undergo diagnostic assessment for symptoms suggestive of TB, resulting in over 5,000 cases of TB diagnosed each year. Stopping the use of the existing, inadequate tests could save the NHS a lot of money. In contrast, the new, more accurate rapid blood test, will improve and accelerate diagnostic assessment of patients with suspected TB.”
TB is a bacterial infection affecting the lungs, causing cough, weight loss and fevers, and is spread through droplets from coughs and sneezes from infected patients. Diagnosing and treating the condition early is essential for the health of the patient as well as for preventing the spread of TB to others. There is therefore a need for rapid, convenient tests to rule out a TB diagnosis in suspected cases based on a blood sample.
’Inadequate tests’While laboratory cultures of patient samples, such as sputum or invasive biopsies, are used to confirm the presence of the bacterium, the cultures can take several weeks. A negative result does not rule out a diagnosis of TB, as the bacteria cannot be cultured from samples in a large proportion of TB patients.
Currently available rapid tests for TB used by the NHS, known as interferon-gamma release-assays (IGRAs), can help to indicate if a patient has TB infection by detecting their immune response to TB bacteria based on a blood sample. The findings would then be confirmed with cultured patient samples in the laboratory.
In the latest prospective study, co-led with Professor Onn Min Kon of Imperial College Healthcare NHS Trust , researchers compared existing commercially available IGRA tests against new generation tests in 845 patients with suspected TB in 10 NHS hospitals in England. Patient blood samples were analysed using both sets of tests, the results of which benchmarked against a confirmed diagnoses based on positive culture results.
Analysis of the rapid test results revealed that the second-generation test has a diagnostic sensitivity of 94% in patients with confirmed TB - meaning it gives a positive result for 94% of patients with infection - significantly and substantially higher than either of the existing commercially available IGRA tests (which range from 67.3% and 81.4%).
The findings indicate the test would be much more accurate at ruling out TB infection in suspected cases of TB, so saving time and resources and enabling patients to receive treatment more rapidly.
Improving diagnosticsAccording to the researchers, the medical need for better TB diagnostics is so high that despite a lack of evidence to support their use in patients with suspected TB, existing tests are widely used in clinical practice in the UK and other developed countries. They add that stopping use of the existing tests could save the NHS over £2 million per year, with further savings likely generated by implementing the new tests - which could be available to health services within one to two years, pending regulatory approval.
“Our study shows definitively that existing rapid tests are not effective enough for diagnosing active TB and should not be used. This important result will change clinical practice,” explained Professor Lalvani.
“Existing rapid tests are not recommended for use in patients with active TB because of a lack of evidence that they are clinically useful. But because the clinical need for better diagnosis of TB is so high, they are nonetheless widely used in hospitals."
Professor Lalvani, added: “This study provides definitive, generalizable evidence on the clinical utility of the new test. The next step is now to take this new test through regulatory approval so that it can be made commercially available and used in routine clinical practice.”
The research was funded by the National Institute for Health Research (NIHR) .
‘ Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study ’ by Hilary S Whitworth et al. is published in Lancet Infectious Diseases. DOI: 10.1016/S1473-3099(18)30613-3
The researchers looked at two commercially available IGRA tests, T-SPOT.TB and Quantiferon-Gold-In-tube. The second-generation test incorporates TB antigens (proteins or fragments of the TB bacteria) that are strongly recognised by the immune cells of patients with TB infection. These new antigens are used in the generic ELISpot (enzyme-linked immunospot) platform technology on which the commercial T-SPOT.TB test is based. Photos and graphics subject to third party copyright used with permission or © Imperial College London.
Communications and Public Affairs